NEWS

WIRES

OTHER

Barrier Therapeutics to Present at 24th Annual JPMorgan Healthcare Conference

Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, today announced that Geert Cauwenbergh, Ph.D., Chairman and Chief Executive Officer and Al Altomari, Chief Commercial Officer are scheduled to provide an update on the Company at the 24th Annual JPMorgan Healthcare Conference.

The conference will be held at the Westin St. Francis in San Francisco on January 9-12, 2006. Dr. Cauwenbergh and Mr. Altomari are scheduled to present on Wednesday, January 11th at 11:00 a.m. Pacific Time (2:00 p.m. Eastern).

The presentation will be available live via a webcast and can be accessed through Barrier Therapeutics' corporate website at: http://www.barriertherapeutics.com. An archive of the presentation will be available for replay following the conference.

About Barrier Therapeutics, Inc.

Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. The Company currently markets Solage® (mequinol 2%, tretinoin 0.01%) Topical Solution in the U.S. and Canada for the treatment of solar lentigines, a common condition also known as "age spots," and markets VANIQA®, (eflornithine hydrochloride) Cream 13.9% for slowing the growth of unwanted facial hair in women in Canada. Barrier has eight product candidates in various stages of clinical development. The four most advanced product candidates include Vusion(TM) (formerly known as Zimycan(TM)) for the treatment of diaper dermatitis complicated by candidiasis, Sebazole(TM), for the treatment of seborrheic dermatitis, which are under FDA review, and two other product candidates in Phase 3 for the treatment of onychomycosis and congenital ichthyosis, respectively. Barrier has product candidates in earlier stages of clinical development for the treatment of acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. Web site: http://www.barriertherapeutics.com.

Distributed by Market Wire